Navigation Links
Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
Date:6/18/2013

lete the Acquisition); the anticipated size of the markets and continued demand for Actavis' and Warner Chilcott's products; the impact of competitive products and pricing; access to available financing (including financing for the Acquisition or refinancing of Actavis or Warner Chilcott debt) on a timely basis and on reasonable terms; maintaining a position in the Standard & Poor's 500; the risks of fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Actavis' and Warner Chilcott's manufacturers, facilities, products and/or businesses; changes in the laws and regulations affecting, among other things, pricing and reimbursement of pharmaceutical products; changes in tax laws or interpretations that could increase Actavis' consolidated tax liabilities; the loss of key senior management or scientific staff; and such other risks and uncertainties detailed in Actavis' periodic publi
'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis
2. Actavis and Medicines360 Announce Partnership to Advance Womens Access to Affordable IUDs
3. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
4. Actavis, Inc. to Present at the Goldman Sachs 34th Annual Global Healthcare Conference 2013
5. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
6. Actavis NDA for Progestin-Only Patch Accepted for Filing by FDA
7. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
8. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
9. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
10. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
11. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... statement by Michael J. Sullivan, Pharmaceutical Industry Labor-Management Association Chair: ... to advance a national  innovation agenda, one that stands to ... part: what can the administration and  Members of Congress specifically ... quality of life for working Americans? The President did a ...
... -- American Oriental Bioengineering, Inc. (NYSE: ... company dedicated to improving healthcare through the development, ... prescription and over-the-counter ("OTC") products, today announced that ... Liu and Chief Financial Officer, Ms. Lily Li ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... the open access journal BMC Medicine has found that the ... in India are flawed and the actual number of cases ... are from the Administrative Staff College of India, conducted the ... Medical Sciences in Hyderabad. ,According to the ...
... of his family served in the Indian Army and battled the ... Sena Medal winner// and with ‘Showrya’ meaning ‘brave’ for a name, ... family path. ,But a fall from the first floor ... the one-and-a-half-year-old Showrya Malik, who was pronounced ‘brain dead’ the next ...
... Pradesh government is considering setting up a medical and health ... Health Minister Ajay Vishnoi said Tuesday. ,"The government ... Medical Council of India for opening the university," Vishnoi told ... workshop on Indian medical systems. ,"The need ...
... are not protected from attacks or stroke by taking a ... ,Folic acid or folate is one of the B Vitamins ... medical practitioners prescribe it to prevent cardiac problems. ... Health and Tropical Medicine, New Orleans led a research on ...
... damaging to health, but obesity has higher damaging properties, ... cancers reducing a person’s life span by seven years ... ,Ken Snider, advisor at NICE i.e. National Institute for ... not only to do with weight loss but also ...
Cached Medicine News:Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:A ‘Brave’ Toddler-The Youngest Organ Don 2Health News:Ways to Fight Childhood Obesity 2
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
Iron UIBC (UIBC Buffer + Color + Std.). An Automated analyzer test kits....
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
Medicine Products: